SAN DIEGO, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that George J. Morrow, former Executive Vice President of Global Commercial Operations at Amgen, Inc., has been appointed to Vical's Board of Directors. Mr. Morrow's previous career encompassed significant accomplishments in commercial operations, sales and marketing through a progression of executive management positions at Merck & Co., Inc. and Glaxo Wellcome plc. "We are excited to have George Morrow join our Board of Directors," said Vijay B. Samant, President and Chief Executive Officer of Vical, "especially at this inflection point in our company's progress as we prepare for the potential commercialization of Allovectin ®. George has a proven record of leadership over nearly 30 years in a series of pivotal assignments with three of the world's most successful biopharmaceutical companies. We are eager to draw on his highly relevant experience and keen insights as we advance our potentially paradigm-shifting new treatment for metastatic melanoma." George J. Morrow Mr. Morrow joined Amgen in 2001 as Executive Vice President, Worldwide Sales and Marketing, and advanced in 2003 to Executive Vice President, Global Commercial Operations, a position he held until his retirement in January 2011. Responsibilities in his most recent position included oversight of all commercial functions for Amgen's broad spectrum of products in more than 50 countries worldwide, and the introduction of multiple new products into global markets. From 1992 to 2001, Mr. Morrow held executive management and commercial positions within several subsidiaries of Glaxo Wellcome, including Group Vice President for Commercial Operations (U.S.), Managing Director (U.K.), and most recently as President and Chief Executive Officer of Glaxo Wellcome, Inc. (U.S.). His prior experience at Merck, from 1982 to 1992, included sales and marketing positions culminating as Vice President of Marketing. Mr. Morrow earned a B.S. degree in chemistry from Southampton College, Long Island University; an M.S. degree in biochemistry from Bryn Mawr College; and an M.B.A. degree from Duke University's Fuqua School of Business. He is a member of the Board of Directors of Align Technology, a global medical device company, and was a member of the Board of Directors of Human Genome Sciences, Inc., a biopharmaceutical discovery and development company, from March 2011 until its acquisition in August 2012 by GlaxoSmithKline plc. Mr. Morrow has served previously on boards for Glaxo Wellcome, Inc., the Johns Hopkins School of Public Health, and the Duke University Fuqua School of Business.